Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. It also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects. Alcaftadine was more effective than placebo and at least as effective as olopatadine 0.01% in preventing ocular itching at 15 minutes and at 16 hours after administration[3]. Over a range of formulations and concentrations (0.05%-0.5%), alcaftadine was well tolerated and subjects reported little or no discomfort or taste perversion in any treatment group. Topical administration of alcaftadine 0.25% ophthalmic solution was well tolerated and had an acceptable safety profile[4]. Once-daily alcaftadine 0.25% ophthalmic solution demonstrated greater efficacy in prevention of ocular itching compared with olopatadine 0.2% at 3 min post-CAC (conjunctival allergen challenge) (primary endpoint), and over all time points, 16 h post-treatment instillation. Alcaftadine and olopatadine both provided effective relief compared with placebo and were generally well tolerated[5].
United States, New Jersey
... 展开 >>
STARx Research Center
Recruiting
Edison, New Jersey, United States, 08820
Contact: Erika Julca, lpn,crc 732-906-1747 ejulca1@gmail.com
Contact: June Pepe, lpn, ccrc 973-912-9817 pepejune@gmail.com
Principal Investigator: Jayesh Kanuga, MD
Sub-Investigator: Ligaya Centeno, MD
Sub-Investigator: Ruby Reyes, MD
Sub-Investigator: Leonard Bielory, MD
STARx
Recruiting
Springfield, New Jersey, United States, 07081
Contact: Leonard Bielory, MD 973-912-9817 DrLBielory@gmail.com
Sub-Investigator: Leonard Bielory, MD 收起 <<
搜索
